LUMENIS ANNOUNCES NEW DENTAL PRODUCT AND REORGANIZED DENTAL SALES ORGANIZATION

Yokneam, Israel, March 30, 2005 – Lumenis^® Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications today announced a new global strategy for expanding the dental segment of its medical laser business.

Lumenis has restructured its sales and marketing efforts based on expected growth in the dental market. Effective March 1, 2005, Lumenis established a direct sales force and sales management team as part of its existing Americas’ sales management organization. The Company previously had relied on independent representatives for most of its sales force.

These organizational changes will be further supported by Lumenis’ new AquaLite™ Er:YAG/CO2 combination laser system. The AquaLite is the only combination laser on the dental market designed for both hard and soft tissue procedures. The AquaLite includes the newly introduced illuminated contra-angle handpiece, touch screen control with pre-set operating parameters for 108 hard and soft tissue procedures and several improvements that make the system even easier to use. This introduction follows the most recent FDA clearance for contact cutting of bone tissue.

“We believe we must focus and invest more aggressively in the dental market to command a more significant market share. With the launch of AquaLite and our most recent FDA approval for contact bone cutting, Lumenis is positioned as the technological leader in dental lasers,” said Avner Raz, President and Chief Executive Officer of Lumenis. “Our strategy moving forward will be to integrate these market leading dental technologies into our global sales and marketing organizations, improving our role in this growing segment.”

About Lumenis

Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com.

Contact:

Lauri Hanover, CFO
1-866-232-6803
+972-4-959-9122

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of its Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.